Magalie Joris - Concepedia

Author

Magalie Joris

Centre Hospitalier Universitaire Amiens-Picardie

Also Known As

Jean-Marc Doise, Joris, Magalie, M Joris, M. JORIS, M. Joris, Magalie Joris

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire Amiens-Picardie Inserm Hôpital Saint-Louis Assistance Publique – Hôpitaux de Paris Sorbonne Université

About

Magalie Joris is an author at Centre Hospitalier Universitaire Amiens-Picardie specializing in medicine, immunotherapy, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	314
2	Immunology	4	4	300
3	Pathology	4	4	300
4	Health Sciences	1	1	68
5	Clinical Immunology	1	1	24

Magalie Joris

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Nature Medicine	2022	343
Transthoracic echocardiography: an accurate and precise method for estimating cardiac output in the critically ill patient Pablo Mercado, Julien Maizel, Christophe Beyls, Critical Care	2017	186
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, Blood Aggressive B-cell LymphomaImmunologyPathologyImmunotherapyEarly Failure	2022	131
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort Edmond Chiche, Ramy Rahmé, Sarah Bertoli, Blood Advances	2021	107
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial Roch Houot, Emmanuel Bachy, Guillaume Cartron, Nature Medicine	2023	84
ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases Gandhi Damaj, Magalie Joris, Marie‐Olivia Chandesris, PLoS ONE Hematological MalignancyAutoimmune DiseaseSclerodermaMedicineSystemic Mastocytosis	2014	77
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, Blood Advances Lysa StudyImmunologyPathologyT CellsImmunotherapy	2023	68
The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm Vincent Marmouset, Magalie Joris, Lavinia Merlusca, Hematological Oncology	2019	27
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia Yves Chalandon, Philippe Rousselot, Sylvie Chevret, Blood	2024	25
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma Pierre Sesques, Amy A. Kirkwood, Mi Kwon, Journal of Hematology & Oncology Clinical ImmunologyImmunodeficienciesT-regulatory CellImmunologyImmune Regulation	2024	24

Page 1